CN101801936B - 安立生坦的代谢物和衍生物 - Google Patents

安立生坦的代谢物和衍生物 Download PDF

Info

Publication number
CN101801936B
CN101801936B CN2008801071505A CN200880107150A CN101801936B CN 101801936 B CN101801936 B CN 101801936B CN 2008801071505 A CN2008801071505 A CN 2008801071505A CN 200880107150 A CN200880107150 A CN 200880107150A CN 101801936 B CN101801936 B CN 101801936B
Authority
CN
China
Prior art keywords
ambrisentan
metabolites
metabolite
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801071505A
Other languages
English (en)
Chinese (zh)
Other versions
CN101801936A (zh
Inventor
L·S·小麦尔温
M·尤尔里奇
H-G·海格
J·维曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Gilead Colorado Inc
Original Assignee
Abbott GmbH and Co KG
Gilead Colorado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG, Gilead Colorado Inc filed Critical Abbott GmbH and Co KG
Publication of CN101801936A publication Critical patent/CN101801936A/zh
Application granted granted Critical
Publication of CN101801936B publication Critical patent/CN101801936B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2008801071505A 2007-07-31 2008-07-31 安立生坦的代谢物和衍生物 Expired - Fee Related CN101801936B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95305307P 2007-07-31 2007-07-31
US60/953,053 2007-07-31
PCT/US2008/009236 WO2009017777A2 (en) 2007-07-31 2008-07-31 Metabolites and derivatives of ambrisentan

Publications (2)

Publication Number Publication Date
CN101801936A CN101801936A (zh) 2010-08-11
CN101801936B true CN101801936B (zh) 2012-10-03

Family

ID=39924953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801071505A Expired - Fee Related CN101801936B (zh) 2007-07-31 2008-07-31 安立生坦的代谢物和衍生物

Country Status (8)

Country Link
US (1) US8217155B2 (enExample)
EP (1) EP2183223A2 (enExample)
JP (1) JP2010535210A (enExample)
CN (1) CN101801936B (enExample)
AU (1) AU2008282773B8 (enExample)
CA (1) CA2695259C (enExample)
MX (1) MX2010001255A (enExample)
WO (1) WO2009017777A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
PL2101777T3 (pl) 2006-12-12 2015-10-30 Gilead Sciences Inc Kompozycja do leczenia nadciśnienia płucnego
JP2010535210A (ja) 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
DK2637664T3 (en) 2010-10-15 2017-06-19 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONAL HYPERTENSION
CN102276536B (zh) 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103012281B (zh) * 2011-09-22 2015-04-08 江苏康缘药业股份有限公司 一种手性2-[(4,6-二甲基嘧啶-2-基)氧基]-3-甲氧基-3,3-二苯基丙酸的消旋化方法
CN104280480B (zh) * 2013-07-02 2016-12-28 天津药物研究院有限公司 一种分离检测安立生坦及其有关物质的方法
CN104515816B (zh) * 2013-09-29 2016-04-20 天津药物研究院 一种安立生坦原料及制剂有关物质的检测方法
CN104359993B (zh) * 2014-12-09 2016-03-30 江苏康缘药业股份有限公司 一种安立生坦有关物质的检测方法
EP3235496A1 (en) * 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19726146A1 (de) * 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19806438A1 (de) 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
PA8652001A1 (es) * 2004-11-05 2006-10-13 Wyeth Corp Metabolitos glucuronidos de tigeciclina y epimeros de los mismos
US20090131441A1 (en) * 2005-01-25 2009-05-21 Dompe Phar.R.Ma S.P.A. Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them
JP2008528627A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． グルクロン酸化されたネビボロール代謝産物
EP1891041A1 (en) * 2005-06-17 2008-02-27 Pfizer Products Incorporated METABOLITES OF 1- [-6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL]-3- [2- (4-METHYL-PIPERAZIN-I-YL) -BENZYL]-PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS
PL2101777T3 (pl) 2006-12-12 2015-10-30 Gilead Sciences Inc Kompozycja do leczenia nadciśnienia płucnego
CA2669535A1 (en) 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorders
JP2010535210A (ja) 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19726146A1 (de) * 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten

Also Published As

Publication number Publication date
US20100204163A1 (en) 2010-08-12
WO2009017777A3 (en) 2009-04-09
CN101801936A (zh) 2010-08-11
EP2183223A2 (en) 2010-05-12
AU2008282773A1 (en) 2009-02-05
AU2008282773B2 (en) 2012-11-08
MX2010001255A (es) 2010-12-06
AU2008282773B8 (en) 2013-03-07
CA2695259C (en) 2016-05-24
JP2010535210A (ja) 2010-11-18
US8217155B2 (en) 2012-07-10
WO2009017777A2 (en) 2009-02-05
CA2695259A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
CN101801936A (zh) 安立生坦的代谢物和衍生物
US12240849B2 (en) Nitrogen-containing spiro derivative as RET inhibitor
KR102365535B1 (ko) 2,6-디아미노 피리딘 화합물
CN109721527B (zh) 一种新型抗pd-l1化合物、其应用及含其的组合物
WO2020247429A1 (en) Pyrrolidine compounds
WO2017129116A1 (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
CN107253933B (zh) 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途
US20080280971A1 (en) Deuterium-enriched atorvastatin
JP2018538355A (ja) ベンズアミド誘導体
ITMI991452A1 (it) Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica
Urabe et al. Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability
KR101386318B1 (ko) 히스타민 ｈ3 수용체의 길항제로서의 이소퀴놀린 및 벤조［ｈ］이소퀴놀린 유도체, 그의 제조 및 치료 용도
US12221432B2 (en) Estrogen receptor antagonist
WO2021169769A1 (zh) 芳香族化合物及其药物组合物和用途
RU2827863C2 (ru) Конденсированное трициклическое соединение в качестве двойного ингибитора pde3/pde4
HK40045261B (en) 2,6-diamino pyridine compounds
HK40045261A (en) 2,6-diamino pyridine compounds
EA040490B1 (ru) Соединения 2,6-диаминопиридина
HK40062570A (en) Estrogen receptor antagonist
CN107304180A (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121003

Termination date: 20180731

CF01 Termination of patent right due to non-payment of annual fee